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Abstract
Prostate cancer is one of the leading causes of death for men in America with a mortality rate of
approximately 1 in 41 men. In this research, we focus on enzalutamide-resistant prostate cancer
cells as cell resistance to enzalutamide is a prevalent issue in treating prostate cancer. A novel
compound library at different doses was tested and each compound's efficacy in inducing
apoptosis in enzalutamide-resistant cells was observed. Furthermore, the mechanism by which
apoptosis was induced in compounds that showed a high efficacy at lower doses was analyzed.
Overall, Darapladib showed promising results in treating cells that have acquired enzalutamide
resistance.
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Background Information and Current Literature Surrounding Prostate
Cancer
What is Prostate Cancer?
The prostate is a male reproductive gland located between the bladder and
penis whose main function is to produce an alkaline fluid that both protects the sperm from the
acidity of the vagina and provides sperm with better motility and nutrition. There are three major
regions in the prostate, the transition, central, and peripheral zones. The transition zone
comprises around 10% of the prostate region and is located “between the bladder and the upper
third of the urethra” (2016). The central zone is around a quarter of the prostate’s mass and is
where the ejaculatory duct is found. Finally, the peripheral zone is the remaining 70% of the
prostate and makes up the majority of the gland.
There are two categories of prostate tumors that take place in different regions of the
prostate. Benign prostate tumors often occur in old age and take place in the transition zone.
These tumors usually lead to a slight increase in the mass of the transition zone and can cause
trouble in urination if the mass of the region is applying pressure to the bladder and urethra. The
more cancerous tumors tend to occur in the peripheral zone and are the focus of much prostate
cancer research. There are many types of prostate cancers, such as small cell carcinomas,
transitional cell carcinomas, and sarcomas; however, the most prevalent form of prostate cancer
are adenocarcinomas. Around 95% of all prostate malignancies tend to be
adenocarcinomas (Routh, 2005). Adenocarcinoma is a type of a cancer that originates from
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glandular cells. Since most of the cells in the prostate are glandular, it logically follows that most
prostate cancers will be adenocarcinomas.
There are four stages of prostate cancer which are characterized by the location and
spread of the malignant cells. In stages I and II, the tumor is localized and has not spread to any
other region beyond the prostate. In stage III, the cancer has spread to nearby tissues and is often
known as locally advanced prostate cancer. Finally, in stage IV, the cancer has spread to other
parts of the body which could include vital organs such as the liver, lungs, and bones. This
spread often occurs when prostate tumor cells detach and gain access to vascular pathways such
as blood vessels and lymph nodes (Routh, 2005). It accomplishes this through a process known
as angiogenesis where the cancer tissue is able to form new blood vessels to gain more nutrients.
When the prostate cancer reaches this stage of metastasis, it is known as “advanced prostate
cancer”.
There are many categories of advanced prostate cancer with two major categories being
castration-resistant prostate cancer and hormone-sensitive prostate cancer. Castration-resistant
prostate cancer occurs when the prostate cancer cell “is growing or spreading even though
testosterone levels are low from hormone therapy” (Li et al., 2016). Androgen Deprivation
Therapy, a form of hormone therapy, is a treatment method often prescribed to patients with
prostate cancer, through either medication or surgery, which artificially lowers the amount of
testosterone in the body. This treatment is used because testosterone interacts with the prostate’s
androgen receptors and causes it to proliferate. Specifically, it leads to the transcription of genes
that secrete peptide growth factors such as insulin-like growth factor 1 (Advanced prostate
cancer, 2021). In castration-resistant prostate cancer, the cell has been able to develop
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mechanisms in which it does not require the use of androgen to grow. These mechanisms include
the tissue creating its own androgens, amplification of the AR proteins, and production of
coactivators that do not rely on androgen binding (Hoimes & Kelly, 2010). Hormone-sensitive
prostate cancer is the preliminary stage before castration-resistant prostate cancer (CRPC) has
developed. In this stage, the cancer has not been exposed to any form of hormone therapy and is
sensitive to treatments such as ADT and other hormone deprivation therapies. According to a
metastudy done on castration-resistant prostate cancer, however, around 10-20% of prostate
cancer patients develop CRPC within 5 years (ED, 2011).
Prevalence of Prostate Cancer, Mortality Rate of Prostate Cancer, and Risk Factors
Prostate cancer is the “second most frequent cancer diagnosis made in men and the fifth
leading cause of death worldwide.” (Rawla, 2019). It has a higher prevalence in developed
countries and the chance of being diagnosed with prostate cancer increases significantly in men
greater than 65 years old. The mortality rate of prostate cancer tends to be inversely related to the
incident rate of prostate cancer around the globe. For example, Asian and African countries have
a lower than average rate of prostate cancer incidence rates ranging around 11.5% and 26.6%
respectively. However, Asian and African countries have the highest mortality rates with African
countries having a mortality rate of around +124.4% and Asian countries having a mortality rate
of around 116.7%. This inverse relationship can be explained by the socioeconomic conditions in
Asian and African countries compared to European countries and the Americas. Developing
countries often do not have the medical resources to combat prostate cancer effectively and
generally detect prostate cancer in its much later stages. In comparison, the 5-year survival rate
of American men who have prostate cancer tends to be 98%.
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There are several risk factors that can determine the likelihood of an individual being
diagnosed with prostate cancer in their lives. These risk factors consist of age, ethnicity, family
history and genetics, diet, vitamins and minerals, lifestyle, and previous medical procedures. In
terms of age, prostate cancer tends to affect elderly men the most. Men below the age of 50 have
a 1 in 350 chance of having prostate cancer; however, this rate increases dramatically to 1 in 52
in men above 50 years old. There is a further increase after the age of 65 where the incidence of
prostate cancer is around 60%. Oftentimes older men may have prostate cancer but their cause of
death is a result of other conditions due to the indolent course of most prostate cancers. When
looking at ethnicity, African American men have the highest rate of prostate cancer in America
at a rate of 157.6. This is due to both biological and socioeconomic factors. For example,
African-American men tend to have a more common chromosome 8q24 variant which has been
associated with a higher rate of prostate cancer. Furthermore, African-American men tend to
have less access to screening resources and thus detect prostate cancer in later stages compared
to other demographics. When examining family history, approximately 20% of patients with
prostate cancer have a member in their family who also have prostate cancer. This can be due to
genetics but also an exposure to similar lifestyle habits. When looking at genetics, mutations in
HPC genes can cause protein malfunctioning which can result in the proliferation of the cancer
cells. This can be seen in a specific HPC gene known as BRCA2 which has been associated with
a higher incidence of prostate cancer. A person’s diet can also have an impact on their chances of
having prostate cancer. Saturated animal fats promote carcinogenesis through androgens,
increase reactive oxidative species, and increase tumor proliferation. Vegetables have been found
to decrease the chance of prostate cancer and other cancers in general with catechins in green tea
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and isoflavones in soy being especially anti-carcinogenic. Vitamins and mineral supplements can
also be a factor when considering incidence rates with Vitamin D, Vitamin E, and Selenium
deficiency leading to an increased rate of prostate cancer. Lifestyle choices can result in
increased prostate cancer incidence rates with higher alcohol consumption, smoking, and obesity
resulting in an increased rate of cancer. For example, a person consuming four alcoholic drinks a
day has a relative risk of 1.21. Other lifestyle choices, such as the consumption of coffee or
increased ejaculation, can have an inverse effect and may actually reduce the rate of having
advanced or lethal prostate cancer. Finally, medical treatments such as diagnostic radiologic
procedures and ultraviolet light exposure can cause DNA damage which could lead to mutations
and eventually cancer. This is often seen in men who have undergone these medical treatments in
their youth in other diseases. In summary, mortality and incident rates of prostate cancer are
often inversely related due to socioeconomic and genetic differences. Furthermore, there are
several risk factors ranging from age, race, diet, and more that can have a major impact on the
likelihood of an individual having prostate cancer (Rawla, 2019).
Current Diagnostic Methods and Treatments of Prostate Cancer
Routine diagnosis for prostate cancer is often done after the age of 50 in males as the
probability of having prostate cancer increases significantly after this age. Although 75% of
prostate cancer diagnosed by standard procedures is asymptomatic (Hahn & Roberts, 1993),
symptoms such as urination abnormalities and pain in the pelvic region can be an indication of
prostate cancer.
Diagnosis of prostate cancer can be done through several methods, however, the most
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common method tends to be a combination of the Prostate Specific Antigen (PSA) blood test and
the Digital Rectal Exam (DRE). PSA is secreted by prostate tissue in the bloodstream and as the
prostate tissue increases due to age the levels of PSA in a human male’s bloodstream tend to
increase as well. These levels can be dramatically increased, however, if the prostate has cancer
as proliferation of the cancer cells can result in artificially higher levels of blood PSA. It is
important to keep in mind that the rise of these PSA levels may not solely be attributed to
prostate cancer. Other common conditions such as Benign Prostatic Hypertrophy (BPH) and
prostatitis can also cause an artificial increase in PSA levels as the prostate tissue size increases
in those conditions as well. Thus, higher PSA levels and prostate cancer have a strong
association but are not always causal in relationship. There are several PSA level thresholds that
physicians check for depending on the age of the patient. The recommended thresholds for men
in their 40s, 50s, 60s, and 70s is “2.5, 3.5, 4.5 and 6.5 ng/mL” respectively (Osterling, Jacobsen,
& Cooner, 1995). Although these PSA levels serve as benchmarks, there have been cases where
a patient’s levels are lower than their age’s cut off and they are still diagnosed with prostate
cancer. Thus, the benchmarks serve as a guide but not as definitive evidence of no cancer
(Descotes, 2019). The DRE is also an important diagnostic tool as it allows the physician to
examine the prostate physically for any irregularities. The physician conducts this examination
by inserting a lubricated finger in the rectum and feeling the prostate gland for any lumps or
enlargements. Although most patients with elevated PSA levels during screening do not have
irregularities in the prostate shape, it still serves as an important tool to notice any obvious
differences in the prostate (Descotes, 2019). As stated before, both the PSA Blood test and DRE
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are not fool-proof measures in detecting prostate cancer but when used in conjunction can give a
clearer idea if a patient has prostate cancer.
The DRE and PSA tests are often followed up with a transrectal ultrasound (TRUS) if
any abnormalities are indicated in the previous two tests. The TRUS test is a biopsy test where a
needle takes a random sample of the prostate for examination. Due to the random targeting of the
needle, the biopsy has “a false negative rate of 15%–46% and a tumor undergrading rate of up to
38% when compared with the final Gleason score at radical prostatectomy” (Kvale et al., 2009).
In order to improve the accuracy of the TRUS biopsy, a targeted MRI-TRUS fusion biopsy
method is being implemented. This method targets the TRUS biopsy needle at specific regions in
the prostate indicated by advanced MRI technology. This essentially reduces the rates of false
negatives as it directs the needle at areas of the prostate where prostate cancer is more likely to
be found. Local staging of prostate cancer along with staging of the lymph nodes is also done by
this multiparametric magnetic resonance imaging (mpMRI) technology. Other technology such
as a bone scan and CT scan can also be used to determine the stage of prostate cancer.
Once a patient has had a biopsy, a grade is assigned to the cancer depending on the
morphology of the prostate cancer tissue. This grading system is known as the Gleason Score.
The Gleason score ranges from a score of 6 to 10 with a score of 6 being classified as a lowgrade cancer and a score of 8-10 being classified as a high grade cancer. This score is determined
by rating the primary and secondary patterns of the cancer on a range of 3 to 5 and combining
them to get a final score of 6 to 10. A score of 3 is given when the tissue looks normal while a
score of 5 is given when it looks the most abnormal (Board, 2020).
Following the grading of the biopsy, the physician creates a treatment plan dependent on

7

several factors such as age, previous medical history, potential side effects, and the wishes of the
patient. Prognosis of the treatment is dependent on these factors as well. In general there are
seven types of standard treatment options that are used. These treatment options are watchful
surveillance, surgery, radiation therapy, hormone therapy, chemotherapy, immunotherapy, and
bisphosphonate therapy. Watchful surveillance often occurs in indolent prostate cancers that may
have the potential to become malignant. In these cases, only 1 out of a 100 patients with indolent
cancers die from the disease (Localized prostate cancer: Low-risk prostate cancer: Active
surveillance or treatment?, 2020). Thus, it may not be necessary to implement active treatment
measures as they may counterintuitively decrease quality of life. Surgery is often performed on
patients in good health whose tumor may be removed through surgical means. Although there
are many different surgery options, the most common one tends to be a radical prostatectomy. A
radical prostatectomy is a procedure that removes the prostate, seminal vesicles, and surrounding
tissue (Board, 2020). By removing the prostate, it significantly reduces the chance of the cancer
metastasizing. However, side effects such as impotence and erectile dysfunction often follow
after the completion of this procedure. Radiation therapy is another treatment option that uses
high energy x-rays or other types of radiation to eliminate prostate cancer cells. There are many
different types of radiation therapy from external, internal, and radiopharmaceutical. Although
this mode of treatment can often be effective, it may have damaging side effects such as an
increased rate of bladder and/or gastrointestinal cancer along with impotence and urinary
dysfunction. Hormone therapy can also be an effective way to indirectly reduce the prostate
cancer cells by reducing the amount of androgens in the body. Androgen Deprivation Therapy
(ADT) is implemented in many cases of prostate cancer because testosterone and other
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androgens often act to induce growth signals in prostate cells. Studies have shown that
intermittent over continuous treatment of these therapies is more effective because it delays drug
resistance and side effects of the therapy. By artificially reducing the amount of androgens in the
body, other areas in the body that are impacted by androgens are also affected. Thus, ADT and
other hormone therapy can often lead to sexual dysfunction and take a toll on the mental health
of a patient. Chemotherapy is a drug-based approach where the drug is able to travel the
bloodstream and destroy the cancer cells systemically. A problem with this therapy, however, is
that the “mechanisms of activity of chemotherapy agents are not cancer-specific” (Beer &
Bubalo, 2001). Thus, normal tissue cells around the prostate can also be susceptible to the
cytotoxic effects of these drugs. Immunotherapy in prostate cancer is able to take advantage of
the patient’s immune system in order to fight the cancer. For example, antibodies to human
CTLA-4 can help increase the function of T cells in the body and result in greater targeting of
cancer cells (Madan, Gulley, &amp; Kantoff, 2013). Another common immunotherapy is
Sipuleucel-T which uses a vaccine to activate the patient’s immune system. Challenges can
present itself when using immunotherapy, however, including “the inability to predict treatment
efficacy and patient response; the need for additional biomarkers; the development of resistance
to cancer immunotherapies; the lack of clinical study designs that are optimized to determine
efficacy; and high treatment costs” (Ventola, 2017). The final commonly prescribed treatment
option, Bisphosphonate Therapy, mainly deals with reducing cancer spread to the bone. A side
effect of Androgen Deprivation Therapy is that it often leads to an increase in bone loss. In order
to combat this, bisphosphonate therapy is implemented to reduce bone fractures and reduce
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metastases in the bones. Implementation of these drugs can be very effective, but can also lead to
certain bone defects in other parts of the body.
Innovative treatments have also started to be used in clinical trials including cryosurgery,
high-intensity-focused-ultrasound therapy, proton beam radiation therapy, and photodynamic
therapy. Although these therapies show much promise, they still need to be tested more
thoroughly in order to be used as more standardized treatment.
Prostate Cancer at a Molecular Level
On a molecular level, prostate cancer development and proliferation can be caused by
either hereditary gene mutations or sporadic gene mutations. Although most cases fall in the
sporadic prostate cancer category, around 42% can also be accounted for by heritable factors
(Lichtenstein et al., 2000). According to studies done on familiar inheritance of prostate cancer,
genes associated with prostate cancer can be transferred through all three modes of inheritance
(autosomal dominant, recessive, and X-linked) (Lichtenstein et al., 2000). The two main
autosomal genes to be identified in prostate cancer inheritance are HPC1/RNASEL and PCAP.
RNASEL is a ribonuclease involved in the degradation of cellular and viral mRNA along with
inducing apoptosis in viral infections. Although not confirmed by all studies, many have pointed
that mutations in this ribonuclease may result in inhibition of anti-proliferative mechanisms of
the ribonuclease allowing further growth of the prostate cancer tumor. Another gene that may
play a crucial role in hereditary prostate cancer is CHEK2. CHEK2 regulates p53 in the DNA
damage signaling pathway (Mazaris & Tsiotras, 2013). Thus, mutations in this gene may result
in malfunctioning of tumor suppressing mechanisms which could lead to increased tumor
proliferation in prostate cancer cells.
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When looking at sporadic prostate cancer, the two main gene types that develop
mutations are tumor suppressor genes and proto-oncogenes. The most commonly mutated tumor
suppressor gene is the p53 gene. The p53 gene has a relatively low mutation rate in primary
prostate cancer, 10-20%, but tends to be highly mutated in advanced prostate cancer,
approximately 42% of the time. Proper functioning of the p53 is crucial as it acts as a checkpoint
before a cell goes to the S phase in mitosis as well as inducing apoptosis in cells that have
damaged DNA. Another important tumor suppressor gene is CDKN1B which codes for p27 – a
cyclin dependent kinase inhibitor that often has reduced cellular levels during advanced stages of
prostate cancer. Mutations in the CDKN1B gene resulting in a non-functioning p27 may also
lead to loss of PTEN function, another tumor suppressor gene that is important in cell regulation.
PTEN acts as a tumor suppressor by “inhibiting the phosphatidylinositol 3-kinase-protein kinase
B (PKB-Akt) signaling pathway which is essential for cell cycle progression and cell survival”
(Sun et al., 1999). The main proto-oncogene associated with prostate cancer is c-MYC. c-MYC
is a transcription factor that belongs to a family of helix-loop-helix-leucine zipper proteins
(Garcia-Gutierrez, Delgado, & Leon, 2019). c-MYC promotes cell proliferation by inducing
“positive cell-cycle regulators such as cyclins, CDK’s, and E2F transcription factors” (GarciaGutierrez, Delgado, & Leon, 2019). It also inhibits many of the common cell-cycle inhibitors
such as p15, p21, and p27. Although c-MYC in normal concentrations is not detrimental to the
cell, over-expression of this protein can result in greater tumor growth as seen in about 30% of
advanced prostate cancer cases (Mazaris & Tsiotras, 2013). Another common proto-oncogene in
prostate cancer cells is Bcl-2. Bcl-2 is not commonly expressed in normal prostate cells;
however, it is commonly expressed in advanced prostate cancer cells. Studies have shown that
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Bcl-2 overexpression may be a result of androgen-independent prostate cancer as androgens tend
to down-regulate the expression of Bcl-2. Bcl-2 overexpression often leads to the safeguard of
prostate cancer cells from apoptosis.
Although mutations in both proto-oncogenes and tumor suppressor genes lead to
development of prostate cancer cells, intracellular receptors also play a major role in the
development of prostate cancer. The main intracellular receptor involved in prostate cancer is the
androgen receptor. DHT, produced by the conversion of testosterone via 5ɑ-reductase, is able to
attach to the androgen receptor with great affinity once it enters prostate cells (Lonergan &
Tindall, 2011). Once bound to the AR, the AR is able to enter the nucleus and bind to the DNA
acting as a transcription factor. This propagates the further proliferation of the prostate cancer
cells. Although hormone deprivation therapy is often used to combat this issue, it is generally a
temporary solution. This is because the cell is able to find other mechanisms by which the
Androgen Receptor can still be activated or ways by which the androgen receptor pathway can
be bypassed to produce the same outcomes. For example, when studying metastatic prostate
cancer cells point mutations in the AR gene from CAA to CGA or GCC to ACC were detected.
These mutations prevented the drug analog to bind to the active site. Advanced prostate cancer
cells have also been found to express higher levels of AR transcripts allowing for there to be a
higher concentration of Androgen receptors within the cell (Mazaris & Tsiotras, 2013). This
gives the prostate cancer cell the ability to compensate for the artificially lowered levels of
androgens through Androgen Deprivation Therapy (ADT).
Common Apoptosis Pathways and Mechanisms
Apoptosis is a process by which a cell undergoes programmed death. Apoptosis is a
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normal process and tends to occur during the development of the cell along with acting as a
mechanism to regulate cell populations in tissue (Elmore, 2007). In this project it is important to
understand the mechanism by which apoptosis occurs as a majority of the compounds involved
in limiting the proliferation of prostate cancer cells induce apoptosis in the cell. The process of
apoptosis is often compared to necrosis as both processes lead to the death of a cell. However,
there are several key factors that differentiate the process of apoptosis and necrosis. Apoptosis is
a deliberate process and involves an energy-dependent mechanism. In contrast, necrosis is a
passive process usually caused by some cytotoxicity in the environment. It is not an energy
dependent mechanism and often affects contiguous cells. Apoptosis usually occurs in a single
cell and results in the shrinking of the cell with the cytoplasm retained in apoptotic bodies
(Elmore, 2007), while necrosis causes cell swelling and the release of cytoplasm in the
environment. Although apoptosis is generally considered an irreversible process, scientists have
identified certain conditions in which it can be reversed. For example, mutations in engulfment
genes sometimes allow for the survival and differentiation of cells that were destined for
apoptosis (Reddien, Cameron, & Horvitz, 2001). Generally, weak apoptotic signals and
mutations/removal of macrophages and other engulfment mechanisms may allow the cell to
survive even if caspase has been activated.
When examining the mechanism of apoptosis there are three main pathways by which a
cell conducts apoptosis. These pathways are the extrinsic pathway, intrinsic pathway, and
perforin/granzyme pathway. All of these pathways utilize caspase proteins which are typically in
their inactive form and when activated can initiate the activity of other procaspases, leading to a
protease cascade (Elmore, 2007). The rapid activation of these caspase dependent transduction
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signals allows the cell to amplify apoptosis and lead to rapid cell death. The extrinsic pathway is
also commonly referred to as the “death receptor pathway”, while the intrinsic pathway is
referred to as the “mitochondrial pathway”. Although these pathways may seem independent,
recent studies have shown that certain steps may be interrelated (Igney & Krammer, 2002). All
three pathways also converge at a single point, known as caspase-3, and continue uniformly
down a path known as the “execution pathway”. The execution pathway relies on a
transmembrane death receptor that is part of the Tumor Necrosis Factor (TNF) super family of
receptors. There are many death ligands that bind to this receptor with some examples being
FasL/FasR, TNF-ɑ/TNFR1, and Apo3L/Dr3. The binding of the death ligand induces a
clustering of receptors which recruit several different adaptor molecules. These adaptor
molecules help facilitate the formation of a death signaling complex more commonly known as
DISC. Once DISC is formed, it activates caspase-8 which activates caspase-3. At this point, the
cell enters into the execution pathway. The intrinsic pathway is activated by receptorindependent stimuli and is divided into negative and positive stimuli. Positive stimuli are stimuli
that lead to the activation of apoptotic pathways. These stimuli include radiation, toxins,
hypoxia, etc. Negative stimuli, on the other hand, are stimuli that do not activate apoptosis
directly but rather inhibit apoptotic suppression mechanisms. Both stimuli lead to the opening of
the mitochondrial permeability transition pore (MPT), which leads to the increased permeability
of the inner mitochondrial membrane. This increased permeability has two effects: the dispersion
of the proton gradient and the release of pro-apoptotic proteins. The dispersion of the proton
gradient significantly reduces the amount of ATP generated by the cell and results in energy
deficiency. The release of pro-apoptotic proteins results in the formation of a protein called
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apoptosome, which leads to caspase 9 activation. Caspase 9 is able to activate caspase-3 that then
leads the cell into the execution pathway. The perforin/granzyme pathway is activated by
cytotoxic T (CD8+ cells) in response to antigen markers on the cell surface indicating signs of
infection. In response to these antigens, the cytotoxic T cell creates a transmembrane perforin
molecule, which releases granules containing granzyme B and granzyme A. Granzyme B has the
ability to both directly activate caspase-3 and indirectly activate caspase-3 through caspase-10
activation. As mentioned before, once caspase-3 is activated the cell activates the execution
pathway. Granzyme B can utilize the mitochondrial/intrinsic pathway to accomplish apoptosis.
Granzyme A is able to induce apoptosis through caspase-independent mechanisms. It can
accomplish this by cleaving the SET complex that has a role in DNA repair. By cleaving this
SET complex, the DNA is more prone to cleavage by DNAases, which eventually results in the
degradation of DNA. As mentioned before, all three pathways converge at the execution
pathway. Thus, it is important to understand how the execution pathway is utilized to induce
apoptosis in the cell. The execution pathway is triggered by the activation of caspase-3 and once
caspase-3 is activated, the two main proteins that it activates are endonucleases and proteases. In
terms of endonucleases, the main endonuclease activated is CAD which is cleaved from its
inactive form, ICAD, by caspase-3. CAD is responsible for degrading chromosomal DNA and
condensing chromatin. In terms of proteases, caspase-3, caspase-6, and caspase-7 work in
conjunction to cleave several cytoplasmic and nuclear proteins such as alpha fodrin and NuMA.
The final phase of apoptosis is phagocytic uptake of the cell. This phase is characterized by the
presence of phosphatidylserine on the outer leaflet of the cell membrane which signals for
phagocytic recognition, uptake, and disposal in a noninflammatory fashion (Fadok, Cathelineau,
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Henson, Bratton, & Daleke, 2012). Identifying which apoptotic pathway is used by a novel
compound will help further our understanding of the mechanism by which proliferation of the
prostate cancer cells is inhibited.

16

Specific Aims of the Project
1. Test a library of novel compounds on advanced prostate cancer cells and assess the rate at

which the cells are proliferating in comparison to untreated cells.
2. Identify a compound from the library that has the potential to inhibit proliferation of

advanced prostate cancer cells. Furthermore, identify a compound that has cytotoxic
effects and has the ability to induce apoptosis specific to advanced prostate cancer cells.
3. Once a novel compound has been identified with the ability of inducing apoptosis in

advanced prostate cancer cells, understand the apoptotic mechanism by which it is able to
cause cell death in these cells.
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Methods
Drug Culturing Assay and Prostate Cancer Cell Line
To conduct the drug screening and viability assay I selected the Lymph Node
Carcinoma of the Prostate Enzalutamide Resistant (LNCaP-ENR) cell line. The LNCaP cells
were prostate cancer cells that have been desensitized to enzalutamide drugs. These types of cells
are normally present in stage I-II of prostate cancer (Ravenna et al., 2014).
In order to maintain these cell lines, several reagents were used. Initially, the
cells (~300,0000) were plated in a 60 mm diameter plate (Falcon) with RPMI 1640 (Thermo
Fisher Scientific) media and 10% Fetal Bovine Serum (FBS). The RPMI 1640 media contains
important nutrients for the cell to survive including Biotin, Vitamin B , and PABA, while the
12

10% FBS includes growth factors and antibodies to aid in cell growth and immunity. The cells
were incubated at 37℃ for 48 hours in a CO incubator. Once the plates have reached 70%
2

confluency, the cells were divided into half in order to prevent stationary/death phase. The
confluency of the cell plate was verified by observing the tissue plate under a compound
microscope. There were several steps taken to reduce the cell population in half. First, the old
media was discarded and Dulbecco’s Phosphate-Buffered Saline (dPBS) was added to remove
any cellular junk from the plate. Once the dPBS had taken up all of the cellular junk it was also
discarded in the same manner as the old media. In order to lift the cells off of the plate, trypsin
was added and the cells were incubated with the trypsin mixture for a couple of minutes. It is
important not to prolong this step as long term cellular exposure to trypsin can actually be
damaging to the cell line. After a couple of minutes, the trypsin was neutralized with 2-3 times
the amount of RPMI 1640 and 10% FBS. The cellular mixture was then homogenized through

18

micropipetting and half of the mixture was transferred to a new plate. Thus, the new plate had
50% of the cells from the old plate and the old plate was discarded. The new plate also received
additional RPMI 1640 media with 10% FBS in order to ensure proper growth of the cells. The
final plate was incubated at 37℃ and the reduction process was repeated after another 48 hours.
The proper maintenance of these cells was crucial in receiving accurate data when these cells
were treated with varying novel compounds in the drug screening and viability assay (Ghosh,
2004).
Drug Screening Assay
The drug screening and viability assays allow us to test several novel compounds at
different dosages and assess their ability to induce apoptosis in the cancer cell lines. In order to
run this assay, approximately 2,500 cells were seeded per well in a 96 well plate. Each well also
consisted of RPMI and 10% FBS to ensure the survival of the cells in the well. The total volume
in each well was standardized to a 100 µL. The 96 well plate was then incubated for 72 hours at
37℃ in a CO incubator. Along with the cells being based in the RPMI media and 10% FBS, the
2

cells also received a varying dosage of different novel compounds. Furthermore, there were a
couple of cell wells that did not receive any dosage of the drug to serve as the control. The
dosage of each compound increased in constant increments depending on the strength of the
compound. Once 72 hours had passed, the viability of the cells was checked through an
MTS/PES One Solution Cell Titer Assay (Promega Corp, Madison, WI).
MTS/PES One Solution Cell Titer Assay and Cell Viability
The MTS/PES One Solution Cell Titer Assay was used to determine the number of cells
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that were still viable in a well after 72 hours of administering a certain dosage of a novel
compound in the well. This assay primarily works by detecting the amount of ATP in a well and
correlating the amount of ATP to the presence of metabolically active cells. In the MTS/PES
One Solution Cell Titer Assay, the main compound that reacts with ATP is Luciferin. The
reaction is catalyzed by magnesium and results in fluorescence of the compound once the
reaction is completed. The level of fluorescence of each individual well was detected by a plate
reader and absorption values were read through a connected monitor. These absorbance values
were then used to determine the amount of ATP in the solution which was correlated to the
amount of viable cells in the solution. Promega provides a standard curve correlating absorbance
values and the number of cells in a solution as long as the cell media volume of each well in the
96 well plate is at a 100 µL. When looking at the MTS/PES One Solution Cell Titer Assay
protocol, the first step required was the thawing of the Cell Titer Assay reagent from -70℃ to
room temperature. It was important to have this temperature change take place gradually as a
sudden change in temperature could have lead to the breaking of the tube. Furthermore, it is
recommended not to have the reagents exceed a temperature of 25℃ as it can cause the reagents
to denature. Once the Cell Titer Assay reagent had been properly thawed, 20 µL was added to
each of the 100 µL cell media volumes in the 96 well plate. It was crucial to keep the reagent in a
dark environment prior to addition as it prevented the fluorescence process from beginning early.
Once the reagent had been added, the 96 well plate was shaken for two minutes in order to
properly homogenize the mixture and allow the cells to lyse. After the two minutes were over,
the plate was incubated at 37℃ for ninety minutes in order to allow the reaction between the
luciferase and ATP to properly take place. By performing this assay, analysis of which
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compounds were more effective in inducing apoptosis in the cancer cell lines becomes much
simpler (Cell-Titer Glo 2.0 Assay, 2018).
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Experimental Design
Collecting data for each novel compound took place over a week. Each week, cells were
seeded in the 96-well plate using the existing cell line, novel compounds were added in a dose
dependent manner, and the MTS assay was conducted. The sections below go into detail
regarding each of these phases.
Seeding 96-Well Plate
Before seeding the 96-well plate, the 60 mm cell plate containing the cell line was first
observed under a microscope for confluency and contamination. Once the cells were ensured to
be healthy and in proper confluency, they were trypsinized in order to detach from the 60 mm
cell plate. RPMI media was then added to the mixture and the cells were aspirated thoroughly to
maintain homogeneity. Approximately 500 µL was taken from the mixture and placed in a
ViCell Cell Counter to determine the total cell count of the plate. The ViCell Cell Counter used
Trypan Blue Dye to stain the cells in the 500 µL sample and differentiate between viable and
non-viable cells.
Once the total cell count of the 60 mm cell plate was obtained, a dilution mixture was
created consisting of cells and media to achieve a cell concentration of 2,500 cells per 100 µL. In
order to avoid contamination, only the internal wells were seeded with cells. Thus, only 60 wells
out of the 96 wells were seeded. Each well consisted of 2,500 cells and 100 µL of total volume.
The dilution mixture was created with a total volume of 6.5 mL instead of 6 mL to account for
any margin of error in the pipettes. All the wells were pipetted in a column-by-column manner
and with approximately the same angle to maintain a controlled environment. Once all of the 60
wells were seeded, the 96-well plate was kept at 37℃ in a CO incubator for 24 hours.
2
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Addition of Novel Compounds
Prior to the addition of the novel compounds, the 96-well plate was observed under a
microscope to ensure that each well had the same number of cells and that the cells were
attached in approximately the same location. Initially, many wells were removed as they did not
contain the same number of cells resulting in fewer novel compounds being tested. As the project
continued, however, the consistency in pipetting the wells improved and more compounds were
tested at a time. Once any erroneous wells were crossed out, the remaining wells were labeled
with both the drug that was going to be added as well as the concentration.
Initially, all of the novel compounds came in a 50 mM stock concentration. Since most
of the dosages fell between 2 µM to 30 µM, the compounds had to be diluted using 10% DMSO.
Once the proper dilutions had been created, each dose was added in a triplicate in order to
minimize the margin of error. In addition, three wells were kept as controls with no novel
compounds added and three wells solely consisted of media to act as a blank. The novel
compounds were pipetted into the wells in an identical manner and the control wells were
located in close proximity to the experimental wells to replicate similar conditions. Once all of
the novel compounds were added, the 96-well plate was kept at 37℃ in a CO incubator for 72
2

hours. In the beginning of the project, only two novel compounds at different dosage
concentrations were tested at a time. As time went on, however, around four novel compounds
were tested at different dosage concentrations at a time. This allowed for a significant increase in
the total number of novel compounds that were able to be screened by the end of the project.
Conducting MTS Assay
23

To initiate the MTS assay, the MTS reagent is thawed gradually from a temperature of
-70 ℃ to room temperature using a water bath. During this thawing process, the reagent is kept
in a dark environment to prevent the reagent from reacting with light prior to addition. Once the
reagent has been thawed, 20 µL of the reagent is added to each of the internal wells in the 96well plate. The reagent is pipetted in an identical manner to reduce the margin of error. After
adding the reagent, it is lightly shaken for two minutes allowing the mixture to homogenize.
Then, the 96-well plate is kept at 37℃ in a CO incubator for 90 minutes as the luciferase and
2

ATP need adequate time to react. Subsequently, the 96-well plate is then placed in a “blank”
machine where the absorbance value for each well is recorded. The MTS reagent becomes a
darker color with greater cellular activity. Thus, an effective novel compound would exhibit a
lighter color as the dosage of that compound increases in comparison to the control well.
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Results
Apalutamide
Table 1: LNCaP-ENR Percent Cell Viability at Various Apalutamide Concentrations
Percent Cell Viability
10 µM

20 µM

30 µM

74.82394366 102.8169014 107.3943662
73.5915493 100.8802817 100.528169
88.55633803 95.42253521 111.971831

Figure 1: Bar Graph Indicating Mean Percent Cell Viability for LNCAP-ENR cells at different concentrations of
Apalutamide

NVP-TAE 226
Table 2: LNCaP-ENR Percent Cell Viability at Various NVP-TAE 226
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Percent Cell Viability
0.5 µM

1 µM

2 µM

4 µM

8 µM

89.57415565 115.712188 102.8879099 85.26676456 72.7361723
79.78463045 109.8384728 95.05628977 74.30249633 74.79197259
88.88888889 86.93098385 87.71414586 76.84777288 70.87616251

Figure 2: Bar Graph Indicating Mean Percent Cell Viability for LNCAP-ENR cells at different concentrations of
NVP-TAE 226

LRRK2-IN-1
Table 3: LNCaP-ENR Percent Cell Viability at Various LRRK2-IN-1 Concentrations
Percent Cell Viability
0.5 µM

1 µM

2 µM

4 µM

8 µM

124.1311796 103.3773862 92.70680372 59.71610377 43.66128243
121.7816936 94.66470876 84.28781204 55.80029369 40.92021537
122.0753793 92.51101322 75.28144885 54.23396965 38.86441508
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Figure 3: Bar Graph Indicating Mean Percent Cell Viability for LNCAP-ENR cells at different concentrations of
LRRK2-IN-1

AZD-9291
Table 4: LNCaP-ENR Percent Cell Viability at Various AZD-9291 Concentrations
Percent Cell Viability
1 µM

2 µM

4 µM

8 µM

12 µM

96.37023593 78.0399274 49.00181488 3.992740472 1.633393829
98.00362976 77.31397459 33.75680581 4.355716878 2.359346642
95.09981851 66.4246824 35.93466425 4.718693285 2.359346642
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Figure 4: Bar Graph Indicating Mean Percent Cell Viability for LNCAP-ENR cells at different concentrations of
AZD-9291

XMD8-92
Table 5: LNCaP-ENR Percent Cell Viability at Various XMD8-92 Concentrations
Percent Cell Viability
1 µM

2 µM

4 µM

8 µM

12 µM

102.1778584 80.03629764 45.91651543 27.5862069 14.15607985
106.7150635 107.2595281 42.46823956 23.04900181 17.78584392
110.3448276 79.67332123 54.08348457 23.95644283 15.60798548
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Figure 5: Bar Graph Indicating Mean Percent Cell Viability for LNCAP-ENR cells at different concentrations of
XMD8-92

Ibrutinib
Table 6: LNCaP-ENR Percent Cell Viability at Various Ibrutinib Concentrations
Percent Cell Viability
1 µM

2 µM

4 µM

8 µM

12 µM

113.430127 105.2631579 109.9818512 114.3375681 84.75499093
110.3448276 112.522686 110.8892922 100.1814882 88.02177858
100.5444646 99.8185118 104.7186933 103.6297641 74.77313975
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Figure 6: Bar Graph Indicating Mean Percent Cell Viability for LNCAP-ENR cells at different concentrations of
Ibrutinib

CEP-37440
Table 7: LNCaP-ENR Percent Cell Viability at Various CEP-37440 Concentrations
Percent Cell Viability
1 µM

2 µM

4 µM

8 µM

12 µM

100 113.5542169 91.26506024 40.96385542 196.3855422
125.6024096 62.95180723 412.6506024 51.80722892 -1.204819277
126.5060241 77.10843373 80.72289157 50.90361446 -3.915662651
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Figure 7: Bar Graph Indicating Mean Percent Cell Viability for LNCAP-ENR cells at different concentrations of
CEP-37440

Abiraterone
Table 8: LNCaP-ENR Percent Cell Viability at Various Abiraterone Concentrations
Percent Cell Viability
10 µM

20 µM

30 µM

100.695825 95.92445328 101.6898608
118.2902584 113.916501 130.5168986
139.860835 111.4314115 121.1729622
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Figure 8: Bar Graph Indicating Mean Percent Cell Viability for LNCAP-ENR cells at different concentrations of
Abiraterone

Darolutamide
Table 9: LNCaP-ENR Percent Cell Viability at Various Darolutamide Concentrations
Percent Cell Viability
15 µM

20 µM

30 µM

151.2922465 97.41550696 92.64413519
116.2027833 107.4552684 108.9463221
157.8528827 102.8827038 102.8827038
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Figure 9: Bar Graph Indicating Mean Percent Cell Viability for LNCAP-ENR cells at different concentrations of
Darolutamide

Daclatasvir Impurity B
Table 10: LNCaP-ENR Percent Cell Viability at Various Daclatasvir Concentrations
Percent Cell Viability
6 µM

8 µM

12 µM

103.4791252 104.9701789 92.44532803
104.0755467 71.66998012 87.67395626
99.70178926 69.28429423 96.42147117
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Figure 10: Bar Graph Indicating Mean Percent Cell Viability for LNCAP-ENR cells at different concentrations
of Daclatasvir Impurity B

Daclatasvir Impurity C
Table 11: LNCaP-ENR Percent Cell Viability at Various Daclatasvir Impurity C Concentrations
Percent Cell Viability
6 µM

8 µM

12 µM

91.6500994 101.1928429 102.6838966
93.33996024 97.2166998 90.05964215
100.7952286 111.9284294 81.90854871
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Figure 11: Bar Graph Indicating Mean Percent Cell Viability for LNCAP-ENR cells at different concentrations
of Daclatasvir Impurity C

Velpatasvir 12
Table 12: LNCaP-ENR Percent Cell Viability at Various Velpatasvir 12 Concentrations
Percent Cell Viability
4 µM

8 µM

12 µM

16 µM

97.01789264 96.22266402 96.81908549 93.73757455
101.0934394 100.3976143 95.62624254 96.22266402
100 89.26441352 98.31013917 99.70178926
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Figure 12: Bar Graph Indicating Mean Percent Cell Viability for LNCAP-ENR cells at different concentrations
of Velpatasvir 12

Darapladib
Table 13: LNCaP-ENR Percent Cell Viability at Various Darapladib Concentrations
Percent Cell Viability
1 µM

2 µM

4 µM

8 µM

92.31678487 109.6926714 32.26950355 2.364066194
98.34515366 112.4113475 23.40425532 2.127659574
99.52718676 101.4184397 34.86997636 2.718676123
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Figure 13: Bar Graph Indicating Mean Percent Cell Viability for LNCAP-ENR cells at different concentrations
of Darapladib

Varespladib
Table 14: LNCaP-ENR Percent Cell Viability at Various Varespladib Concentrations
Percent Cell Viability
4 µM

8 µM

12 µM

16 µM

121.3709677 128.4274194 122.1774194 112.2983871
131.8548387 145.1612903 122.983871 123.5887097
124.1935484 130.2419355 121.3709677 117.5403226
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Figure 14: Bar Graph Indicating Mean Percent Cell Viability for LNCAP-ENR cells at different concentrations
of Varespladib

AZD 4547
Table 15: LNCaP-ENR Percent Cell Viability at Various AZD 4547 Concentrations
Percent Cell Viability
4 µM

8 µM

12 µM

16 µM

99.7983871 88.10483871 61.08870968 61.08870968
81.65322581 70.96774194 56.85483871 55.24193548
92.74193548 70.36290323 58.87096774 57.45967742
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Figure 15: Bar Graph Indicating Mean Percent Cell Viability for LNCAP-ENR cells at different concentrations
of AZD 4547

GW788388
Table 16: LNCaP-ENR Percent Cell Viability at Various GW788388 Concentrations
Percent Cell Viability
4 µM

8 µM

12 µM

16 µM

128.8306452 116.9354839 101.4112903 101.6129032
109.6774194

106.25 95.36290323 91.33064516

99.7983871 103.4274194 102.8225806 105.6451613
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Figure 16: Bar Graph Indicating Mean Percent Cell Viability for LNCAP-ENR cells at different concentrations
of GW788388

Cisplatin
Table 17: LNCaP-ENR Percent Cell Viability at Various Cisplatin Concentrations
Percent Cell Viability
4 µM

8 µM

12 µM

16 µM

115.5241935 120.3629032 120.9677419 115.3225806
110.6854839 109.0725806 120.766129 134.4758065
113.7096774 83.06451613 114.516129 135.8870968
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Figure 17: Bar Graph Indicating Mean Percent Cell Viability for LNCAP-ENR cells at different concentrations
of Cisplatin

Navetiab
Table 18: LNCaP-ENR Percent Cell Viability at Various Navetiab Concentrations
Percent Cell Viability
4 µM

8 µM

12 µM

16 µM

87.2983871 77.82258065 59.07258065 67.74193548
377.4193548

81.25 64.11290323 44.35483871

96.97580645 94.95967742 71.77419355 48.99193548
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Figure 18: Bar Graph Indicating Mean Percent Cell Viability for LNCAP-ENR cells at different concentrations
of Navetiab

Afatiab
Table 19: LNCaP-ENR Percent Cell Viability at Various Afatiab Concentrations
Percent Cell Viability
4 µM

8 µM

12 µM

16 µM

111.4919355 64.11290323 57.66129032 53.02419355
95.36290323 73.79032258 72.58064516 51.20967742
85.48387097 59.47580645 57.45967742 54.63709677

42

Figure 19: Bar Graph Indicating Mean Percent Cell Viability for LNCAP-ENR cells at different concentrations
of Afatiab

Daclatasvir(Selleck)
Table 20: LNCaP-ENR Percent Cell Viability at Various Daclatasvir(Selleck) Concentrations
Percent Cell Viability
4 µM

8 µM

12 µM

16 µM

20 µM

89.09657321 87.69470405 78.97196262 75.54517134 93.92523364
88.94080997 86.13707165 77.25856698 95.63862928 86.44859813
120.8722741 121.9626168 106.3862928 110.1246106 126.9470405
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Figure 20: Bar Graph Indicating Mean Percent Cell Viability for LNCAP-ENR cells at different concentrations
of Daclatasvir (Selleck Brand)

Verteporfin
Table 21: LNCaP-ENR Percent Cell Viability at Various Verteporfin Concentrations
Percent Cell Viability
2 µM

4 µM

8 µM

12 µM

8.885298869 16.47819063 10.50080775 16.80129241
11.14701131 15.02423263 11.63166397 15.02423263
9.8546042 14.86268174 15.34733441 15.83198708
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Figure 21: Bar Graph Indicating Mean Percent Cell Viability for LNCAP-ENR cells at different concentrations
of Verteporfin

Ca3
Table 22: LNCaP-ENR Percent Cell Viability at Various Ca3 Concentrations
Percent Cell Viability
2 µM

4 µM

8 µM

12 µM

39.09531502 32.79483037 30.21001616 28.43295638
33.60258481 34.89499192 36.18739903 26.97899838
40.54927302 31.82552504 30.53311793 24.71728595
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Figure 22: Bar Graph Indicating Mean Percent Cell Viability for LNCAP-ENR cells at different concentrations
of CA3

JNK-Inhibitor 2
Table 23: LNCaP-ENR Percent Cell Viability at Various JNK-Inhibitor 2 Concentrations
Percent Cell Viability
4 µM

8 µM

12 µM

16 µM

102.2016222 93.62688297 85.74739282 85.05214368
84.82039397 86.79026651 82.38702202 92.69988413
87.6013905 74.1599073 82.85052144 87.02201622
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Figure 23: Bar Graph Indicating Mean Percent Cell Viability for LNCAP-ENR cells at different concentrations
of JNK-Inhibitor 2

GSK 3𝛽 Inhibitor VIII
Table 24: LNCaP-ENR Percent Cell Viability at Various GSK 3𝛽 Concentrations
Percent Cell Viability
4 µM

8 µM

12 µM

16 µM

86.67439166 84.2410197 67.4391657 68.71378911
94.55388181 83.42989571 77.75202781 61.18192352
78.67902665 72.19003476 62.45654693 62.10892236
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Figure 24: Bar Graph Indicating Mean Percent Cell Viability for LNCAP-ENR cells at different concentrations
of GSK 3𝞫 Inhibitor
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Figure 25: Cell Morphology of LNCaP-ENR cells treated at different concentrations of Darapladib
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Discussion
In this research, we sought to identify compounds from a novel library which were
effective in inducing apoptosis in advanced prostate cancer cells. Specifically, we observed the
effect of these compounds on LNCaP cells that are resistant to enzalutamide, as it is one of the
leading causes of death in patients dealing with prostate cancer. In order to differentiate effective
and noneffective compounds, the percent cell viability at each dose of the compound was
calculated. This calculation was done by comparing the absorbance values of the control wells
with the experimental wells, while also controlling for the absorbance value given by wells
solely containing media. An effective compound would show a decrease in percent cell viability
as the dosage of the compound increased, while a non-effective compound would either have a
percent cell viability close to a 100% or have an inconsistent trend in regards to percent cell
viability as the dosage increased. Based on this criteria, we identified three effective compounds
that had potential inhibitory effects on advanced prostate cancer cells. These compounds were
AZD-9291, XMD8-92, and Darapladib. AZD-9291 shows a decrease in percent cell viability as
dosage increases especially as the dosage increases from 4 µM to 8 µM which can be seen in
figure 4. XMD8-92 showed a similar trend with a sharp decrease in percent cell viability from 2
µM to 4 µM. Although the percent cell viability was a bit higher than the control at 1µM, this
could be explained by a pipetting error which added a slightly higher cell concentration to the
experimental wells than the cell concentration in the control wells. Darapladib showed the most
significant decrease in percent cell viability as cell death increased drastically from a dosage of 2
µM to 4 µM. Similar to the percent cell viability for XMD8-92 at 1 µM, the percent cell viability
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exceeding a 100% at 2 µM for Darapladib could be due to pipetting errors which increased the
cellular concentration in the cell.
An important issue to note is that, due to time limitations, the assays conducted
using the three effective compounds identified were not replicated. Therefore, the data collected
on these compounds have not been verified for reproducibility. Thus, for researchers looking to
verify this data they may want to consider conducting at least three biological replicates for each
of the compounds of interest.
From the three effective compounds that were identified, Darapladib exhibited the most
inhibitory potential as it decreased the percent cell viability significantly with a relatively small
dosage increase. To further display the apoptotic effect of Darapladib, LNCaP-ENR cells were
plated in several mini plates at a population of approiximately 200,000 cells. Each plate was
treated with a different concentration of Darapladib ranging from 0 µM to 6 µM. These plates
were much larger than the wells in the 96-well plate making it much easier to visualize the
effects of Darapladib on the prostate cancer cells. The cell morphology of each plate is shown in
figure 25 where it can be clearly seen that Darapladib significantly reduces the cellular
population as the dosage increases.
Future Study
In the future, we would like to conduct studies that further examine the apoptotic
mechanism by which Darapladib inhibits LNCaP-ENR cell proliferation. This can be achieved
by identifying proteins released by the cell when Darapladib is treated through assays such as
Western Blotting. Once these proteins are found, we can identify which apoptotic
pathway/pathways are implemented using the information we know about different apoptotic
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mechanisms. Eventually, Darapladib may be a useful compound in combating enzalutamide
resistant advanced prostate cancer and increase quality of life for patients.
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